Trevena Past Earnings Performance

Past criteria checks 0/6

Trevena's earnings have been declining at an average annual rate of -7.8%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 8.6% per year.

Key information

-7.8%

Earnings growth rate

15.5%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate8.6%
Return on equityn/a
Net Margin-6,233.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Trevena Q2 2022 Earnings Preview

Aug 10

Trevena slides on $2M preferred stock offering

Jul 29

Trevena (NASDAQ:TRVN) Will Have To Spend Its Cash Wisely

Jul 08
Trevena (NASDAQ:TRVN) Will Have To Spend Its Cash Wisely

Is Trevena (NASDAQ:TRVN) In A Good Position To Deliver On Growth Plans?

Mar 19
Is Trevena (NASDAQ:TRVN) In A Good Position To Deliver On Growth Plans?

Trevena Offers An Enticing Risk-Reward At These Prices

Dec 14

Trevena: Remaining Patient After A Disappointing Q2 Earnings

Aug 17

Trevena announces resumption of NIH-run trial for TRV734 in opioid use disorder

Jun 16

Trevena's OLINVYK Provides One Of The Most Compelling Growth Profiles

May 10

Trevena Investor Presentation - Slideshow

May 08

Trevena (TRVN) Investor Presentation - Slideshow

Nov 16

Trevena: Reaffirming A Buy On OLINVYK DEA Scheduling

Nov 09

DEA classifies Trevena's oliceridine, distribution to start in November

Oct 30

Revenue & Expenses Breakdown

How Trevena makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:TRVN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241-341813
30 Jun 240-371916
31 Mar 243-402016
31 Dec 233-402016
30 Sep 233-312216
30 Jun 233-382517
31 Mar 230-453017
31 Dec 220-543518
30 Sep 220-613919
30 Jun 220-594217
31 Mar 220-584216
31 Dec 211-523813
30 Sep 211-503713
30 Jun 213-413014
31 Mar 213-332314
31 Dec 203-291913
30 Sep 203-241512
30 Jun 200-271414
31 Mar 200-251413
31 Dec 190-251313
30 Sep 190-261313
30 Jun 193-221411
31 Mar 196-271713
31 Dec 186-311916
30 Sep 186-382120
30 Jun 183-492259
31 Mar 180-602054
31 Dec 170-722049
30 Sep 170-931942
30 Jun 170-107180
31 Mar 172-106170
31 Dec 164-1031690
30 Sep 166-82160
30 Jun 168-63140
31 Mar 168-55140
31 Dec 156-51130
30 Sep 154-48110
30 Jun 153-53110
31 Mar 151-53100
31 Dec 140-5090
30 Sep 140-4390
30 Jun 140-3780
31 Mar 140-3060
31 Dec 130-2450

Quality Earnings: TRVN is currently unprofitable.

Growing Profit Margin: TRVN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TRVN is unprofitable, and losses have increased over the past 5 years at a rate of 7.8% per year.

Accelerating Growth: Unable to compare TRVN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TRVN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: TRVN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 21:01
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Trevena, Inc. is covered by 17 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Difei YangAegis Capital Corporation
Ying HuangBarclays
Jonathan AschoffBrean Capital